Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN and Genome Diagnostics Expands Partnership to Develop Tests for Applications in Prevention and Personalized Healthcare

Published: Friday, June 18, 2010
Last Updated: Friday, June 18, 2010
Bookmark and Share
Extended HLA testing portfolio includes products to assess tolerance for Lumiracoxib and for the early detection of inflammatory diseases.

QIAGEN has announced that it has entered into an agreement with the Dutch molecular diagnostic component supplier Genome Diagnostics which covers the development and commercialization of 6 new tests until 2011.

QIAGEN believes that this collaboration will further expand the Company's testing portfolio for the early detection of diseases and individualized treatment of patients - thereby strengthening QIAGEN's molecular diagnostics offering for applications in prevention and personalized healthcare. Financial details have not been disclosed.

The molecular tests to be developed by Genome Diagnostics target the detection of genetic variations in the so called Human Leukocyte Antigen (HLA) complex. These assays represent the next generation of such tests and are based on QIAGEN's proprietary "Pyrosequencing" and other sequencing technologies.

Other biomarkers targeted by the new tests include the identification of alleles (DNA sequences of a particular gene) within the groups HLA-B*27 and HLA-B*57. The analysis of these genetic variations in the HLA complex allows for the early identification of patients who are at risk of developing disorders such as Morbus Bechterew and other inflammatory diseases, and is thus considered to be an important part in preventing these disorders. It has also been shown that certain alleles within the groups of HLA-B*27 and HLA-B*57 can give information on the development and progress of infectious diseases such as AIDS.

QIAGEN's portfolio already includes several molecular tests for the DNA-based HLA typing in personalized healthcare, among others a method for the detection of the HLA B*5701 biomarker. This genetic variation is associated with a higher risk for adverse reactions to the AIDS drug Abacavir.

In June 2009, QIAGEN announced that it sold parts of its HLA test portfolio for use in transplantation testing to the Swedish investment company LinkMed and retained rights to market those products in areas such as personalized healthcare. QIAGEN and Genome Diagnostics have been working together since August 2006 on the development and commercialization of new product lines in HLA testing. This collaboration is now being expanded through the development of additional tests.

"Sequence based HLA typing is a fast growing market with significant potential", commented Bob Barrett, Vice President Global Marketing, Molecular Diagnostics at QIAGEN. "Since HLA genes are increasingly associated with a growing number of diseases and the patients' response to drugs, HLA testing allows for the assessment of disease risks and for the development of tailored treatments. That's why the tests we develop as a result of this collaboration make a perfect addition to our molecular diagnostics portfolio for applications in prevention and personalized healthcare."

„We are excited to further strengthen our collaboration with QIAGEN", said Wietse Mulder, Managing Director of Genome Diagnostics. "This allows us to expand our unique expertise in sequencing based HLA typing into the field of companion diagnostics, leading to new innovative IVD assays for the field of preventive and personalized healthcare."

Experts believe that the market for HLA typing in personalized healthcare significantly exceeds the volume of the US$ 170 million large transplantation medicine market, where HLA typing was initially used. QIAGEN has not yet announced timelines for submissions to the FDA and for CE-marking in connection with the tests to be developed under the collaboration.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QIAGEN Expands Leadership in Liquid Biopsies
QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the first regulated CTC-based companion diagnostic to guide treatments in prostate cancer.
Tuesday, March 17, 2015
QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
QIAGEN Integrates Content from BIOBASE
The new content expands the world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis.
Wednesday, May 21, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
QIAGEN Acquires Ingenuity Systems
Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics.
Thursday, May 02, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN Unveils Initiative to Create Next-generation Sequencing Portfolio
Company plans to offer sample-to-result workflows that integrate its sample preparation and assay products with a next-generation benchtop sequencer and new bioinformatics.
Tuesday, June 26, 2012
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
Both products receive 510(k) clearance for in vitro diagnostic use in the U.S..
Tuesday, April 17, 2012
QIAGEN Expands Access to State-of-the-Art HPV Screening in China
Coinciding with International Women’s Day, QIAGEN also joins fifth year of campaign to provide free HPV testing to underprivileged women in China.
Thursday, March 08, 2012
QIAGEN and the University of Science and Technology of China Announce Establishment of “QIAGEN Initiative Foundation Professorship”
Sponsored Professorship to be in the field of life sciences
Monday, March 29, 2010
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
Genetic Tug of War
Researchers have reported on a version of genetic parental control in mice that is more targeted, and subtle than canonical imprinting.
Error Correction Mechanism in Cell Division
Cell biologists have reported an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
How to Become a Follicular T Helper Cell
Uncovering the signals that govern the fate of T helper cells is a big step toward improved vaccine design.
Researchers Resurrect Ancient Viruses
Researchers at Massachusetts Eye and Ear and Schepens Eye Research Institute have reconstructed an ancient virus that is highly effective at delivering gene therapies to the liver, muscle, and retina.
Cell Aging Slowed by Putting Brakes on Noisy Transcription
Experiments in yeast hint at ways to extend life of some human cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!